NCT07552077RecruitingPhase 2
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)
Source: ClinicalTrials.gov · Last updated 27 Apr 2026
Brief summary (registry, in English)
The purpose of this study is to evaluate the safety and effectiveness of the experimental drug PTX-022 in the treatment of angiokeratomas
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- First submitted
- 20 Apr 2026
- Start date
- 1 Apr 2026
- Primary completion date
- 31 Aug 2027
- Lead sponsor
- Palvella Therapeutics, Inc.
- NCT number
- NCT07552077
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 15
- From 1 Apr 2026 to the primary completion date, 31 Aug 2027
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any significant concurrent condition that could adversely affect participation
- Patients deemed by the investigator as unwilling or unable to remain compliant with all tests and procedures, including adherence to study drug administration and other protocol-required activities
Other illness
- Any history of allergy or hypersensitivity to sirolimus, or sirolimus-like medications or to PTX-022
Who the study is looking for
- Participants must be 6 years or older
- Diagnosed with angiokeratoma
- Able and willing to comply with all protocol-related activities
- Willing and able to provide written informed consent
Age in the registry: 6 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cleaver Medical Group Coordinator of this site? Confirm its status | Dawsonville | United States | Recruiting |
| Vividia Dermatology Coordinator of this site? Confirm its status | Las Vegas | United States | Not yet recruiting |
| Unified Health Coordinator of this site? Confirm its status | Sherman Oaks | United States | Not yet recruiting |
| Epiphany Dermatology Coordinator of this site? Confirm its status | Southlake | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.